|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.15 EUR | -0.47% |
|
-4.85% | -25.27% |
| 04-25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Formycon AG at it's AGM elected Dr. Thomas Strüngmann to the Supervisory Board and Dr. Andreas Seidl, the future Chief Scientific Officer (CSO), who was appointed to the Management Board by the Supervisory Board effective July 01, 2022.
| 1st Jan change | Capi. | |
|---|---|---|
| -25.27% | 808M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
FORMYCON AG 
